![]() |
市场调查报告书
商品编码
1439268
定量吸入器 - 全球市场回顾、竞争格局、市场预测 (2030)Metered Dose Inhaler Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
2023年全球计量吸入器市场规模预计为166.13亿美元,到2030年将达到214.23亿美元,2024-2030年预测期间复合年增长率为3.99%,预计将增长。 该市场受到COVID-19患病率上升、糖尿病患病率上升、哮喘患病率上升、囊性纤维化病例激增以及慢性阻塞性肺病(COPD)患病率的推动。正增长归因于多种因素,例如消费者数量的快速增加、人口老化的增加以及产品技术进步的增加。 因此,计量吸入器市场预计在 2024-2030 年预测期内将成长。
定量吸入器的市场动态
糖尿病盛行率的增加是定量吸入器市场的主要驱动因素之一。 例如,根据国际糖尿病联盟(IDF)2023年发布的IDF糖尿病图谱第十版,全球20岁至79岁之间约有5.37亿人患有糖尿病。 此外,预计到 2030 年,糖尿病将影响全球 6.43 亿人,到 2045 年,糖尿病将影响 7.83 亿人。 此外,透过定量吸入器施用胰岛素粉末来治疗糖尿病。 因此,糖尿病患者数量的增加将增加对计量吸入器的需求,从而在预测期(2024-2030年)推动全球计量吸入器市场的成长。
此外,推动计量吸入器市场成长的另一个主要因素是气喘盛行率的增加。 例如,根据世界卫生组织(WHO)2023年发布的数据,2019年全球估计有2.62亿人患有气喘。 此外,根据美国气喘和过敏基金会 2023 年发布的数据,2019 年美国约有 2,500 万人患有气喘。 因此,定量吸入器用于治疗气喘。 因此,气喘盛行率的上升将增加对计量吸入器的需求,推动整个计量吸入器市场在预测期内(2024-2030年)向前发展。
然而,缺乏对计量吸入器的认识以及与该设备相关的严重副作用可能会阻碍全球计量吸入器市场的成长。
COVID-19 大流行对计量吸入器市场产生了正面影响。 这是由于COVID-19对肺部的严重影响,估计从COVID-19中康復的患者可能会遭受作为COVID-19后遗症的呼吸道感染,对吸入器的需求激增。 因此,在2024-2030年的预测期内,计量吸入器的需求预计将持续增加。
定量吸入器市场细分分析
在计量吸入器市场的应用领域,慢性阻塞性肺病 (COPD) 预计将在 2023 年占据重要收入。 定量吸入器是便携式、易于使用的设备,能够以气雾剂的形式将气喘药物输送到肺部。 这些药物可与多种慢性阻塞性肺病药物一起使用,包括类固醇(包括 Flobento 氢氟烷 (HFA))、类固醇/支气管扩张剂组合(如 symbicort)和组合药物。 因此,与计量吸入器相关的这些优点可能会增加对计量吸入器的需求并增加整个计量吸入器市场。 另一方面,增加与计量吸入器相关的产品推出也将推动其市场成长。
2020年10月,跨国製药公司Zydus Cadila宣布在印度推出针对慢性阻塞性肺病(COPD)患者的长效毒蕈碱拮抗剂(LAMA)和长效β受体激动剂。宣布推出Forglyn pMDI ,印度首款加压计量吸入器(pMDI)与(LABA)结合。
本报告提供了全球计量吸入器市场的研究和分析,包括市场规模和预测、驱动因素和挑战以及公司和产品概况。
Metered Dose Inhaler Devices Market By Patient Type (Adult And Pedriatric), By Application (Chronic Obstructive Pulmonary Diseases (Copd), Asthma, Covid-19, Diabetes, And Others), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of chronic obstructive pulmonary diseases (copd) and rising prevalence in asthma
The global metered dose inhaler devices market was valued at USD 16,613 million in 2023, growing at a CAGR of 3.99% during the forecast period from 2024 to 2030 to reach USD 21,423 million by 2030. The metered dose inhaler devices market is witnessing a positive growth owing to the various factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings. Therefore, the market for metered dose inhaler devices is estimated to grow during the forecast period from 2024 to 2030.
Metered Dose Inhaler Devices Market Dynamics:
The increased prevalence of diabetes is one of the key factors driving the market for metered dose inhaler devices. For instance, according to the International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth edition released in the year 2023, worldwide, diabetes had affected about 537 million people of age between 20-79 years. Moreover, diabetes can be predicted to affect 643 million people worldwide by 2030 and 783 million people by 2045. Further, insulin powder is administered by metered dose inhalers to treat diabetes. As a result, the demand for metered dose inhaler devices rises due to an increase in diabetes cases, propelling the global metered dose inhaler devices market ahead over the forecast period (2024-2030).
Moreover, another key factor which is responsible for the growth of metered dose inhaler devices market is the increasing prevalence of asthma. For instance, according to the data published by World Health Organization (WHO) in the year 2023, in 2019, asthma afflicted an estimated 262 million individuals globally. Moreover, as per the data published by Asthma and Allergy Foundation of America in the year 2023, in 2019, approximately 25 million people had asthma in the United States. Thus, metered dose inhaler devices are used to treat asthma. Therefore, rising prevalence in asthma increases the demand for metered dose inhaler devices, which drives the overall metered dose inhaler devices market forward over the forecast period (2024-2030).
However, lack of awareness about metered dose inhaler devices and severe side effects associated with the devices, can hamper the global metered dose inhaler devices market growth.
The COVID-19 pandemic has positively impacted the market for metered dose inhaler devices, this can be due to the severe effects of COVID on lungs and it is estimated that people may have respiratory infections as an after effect of COVID, which surged the demand for metered dose inhaler devices among patients recovering with COVID, as well as shortness of breath as its prevalent symptom also contributed to the metered dose inhaler devices demand among COVID patients. Hence, the demand for metered dose inhaler devices will continue to rise in the forecast period from 2024-2030.
Metered Dose Inhaler Devices Market Segment Analysis:
Metered dose inhaler devices market by Patient Type (Adult and Pediatric), Application (Chronic Obstructive Pulmonary Diseases (COPD), Asthma, COVID-19, Diabetes, and Others), Distribution Channel (Online and Offline), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In by application segment of metered dose inhaler devices market, Chronic Obstructive Pulmonary Diseases (COPD) are expected to share a significant revenue in the year 2023. Metered dose inhaler devices are a portable, easy-to-use device that delivers asthma medicine in aerosol form to the lungs. They may be used with a variety of COPD drugs, such as steroids including flovent hydrofluoroalkane (HFA) and a combination of steroid/bronchodilators such as Symbicort, and combination medications. Thus, these benefits associated with the metered dose inhaler devices can increase the demand of metered dose inhaler devices, which could increase the metered dose inhaler devices overall market. However, a rise in product launch associated with the metered dose inhaler devices also drives its market growth.
In October 2020, Zydus Cadila, multinational pharmaceutical company, announced the launch of Forglyn pMDI, India's first pressurized Metered Dose Inhaler (pMDI) with a combination of Long Acting Muscarinic Antagonist (LAMA) and Long Acting Beta Agonist (LABA) for patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in India.
Moreover, due to the interplay of all the factors mentioned above, results in the rising demand for metered dose inhaler devices, which in turn provide a conducive growth environment for overall metered dose inhaler devices during the market forecast of 2024-2030.
North America is expected to dominate the overall Metered Dose Inhaler Devices Market:
Among all the regions, North America is expected to dominate the global metered dose inhaler devices market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the rising prevalence of asthma and surge in cystic fibrosis cases are expected to increase the demand for metered dose inhaler devices in the North American market.
According to the data published by WHO from 3 January 2020 to 21 September 2022, there have been 94,471,064 confirmed cases of COVID-19 in United States. Further, COVID-19 increases the risk of respiratory infections in the patients affecting the lungs. Thus, rising prevalence of COVID increases the demand for metered dose inhaler devices, which surges the growth for metered dose inhaler devices overall market forecast.
Moreover, as per the latest data released by American Lung Association in the year 2020, cystic fibrosis affected approximately 30,000 people in the United States. Also, as per the cystic fibrosis Canada's 2020 annual data report from the Canadian Cystic Fibrosis Registry, released that in 2020, there were 4,332 Canadians with CF, with 62% of them being adults. Further, metered dose inhalers are available for the treatment of cystic fibrosis. Therefore, surge in cystic fibrosis cases would increase the demand for metered dose inhaler devices, which boost the metered dose inhaler devices overall market growth.
Furthermore, the factors mentioned above, provide a conducive growth environment for North American region in metered dose inhaler devices market.
Metered Dose Inhaler Devices Market Key Players:
Some of the key market players operating in the metered dose inhaler devices market include H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others.
Recent Developmental Activities in the Dry Powder Inhaler Devices:
In March 2022, Novartis' Sandoz, a Swiss multinational pharmaceutical corporation, acquired, UK based delivery device development company, Coalesce Product Development Limited, developing a portfolio of inhalation devices. This includes new versions of pressurized metered dose inhalers (pMDI), breath-actuated inhalers (BAI) and pre-metered dry powder inhalers (DPI).
In February 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced the launch of HeroTracker® Sense, a unique digital respiratory health solution that turns a normal metered dosage inhaler (pMDI) into a smart linked healthcare device.
In September 2022, BreatheSuite Inc., a Canadian connected respiratory health startup, announced that its BreatheSuite Metered-Dose Inhaler (MDI) V1 device has acquired 510(K) approval from the US Food and Drug Administration (FDA). The BreatheSuite gadget converts conventional MDIs into smart inhalers by automatically and objectively monitoring and delivering feedback on inhaler adherence and technique for persons with asthma and COPD. It is approved for both prescription and over-the-counter usage.
Key Takeaways from the Metered Dose Inhaler Devices Market Report Study
Target Audience who can be benefited from this Metered Dose Inhaler Devices Market Report Study
Frequently Asked Questions for Metered Dose Inhaler Devices:
The Metered Dose Inhaler device (MDI) is a medication canister that is pressurised and held in a plastic container with a mouthpiece. When sprayed, it delivers a constant and predictable amount of medicine. It is the most widely utilized delivery method for treating asthma, COPD, and other respiratory illnesses.
The global metered dose inhaler devices market was valued at USD 16,613 million in 2023, growing at a CAGR of 3.99% during the forecast period from 2024 to 2030 to reach USD 21,423 million by 2030.
The metered dose inhaler devices market is witnessing a positive market growth owing to the factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings.
Some of the key market players operating in the metered dose inhaler devices market include H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others.
North America is expected to dominate the global metered dose inhaler devices market. Factors contributing to the growth of metered dose inhaler devices market in the North America region are rising prevalence of COVID-19 and surge in cystic fibrosis cases.